ArticleInvestigative ophthalmology & visual science2025
HDAC4 Promotes Neuroprotection of Retinal Ganglion Cells After Optic Nerve Injury.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Purpose: As the sole retinal output neurons, retinal ganglion cells (RGCs) transmit all visual information from the retina to the brain. RGCs do not regenerate, and effective therapies for promoting RGC survival and axon regeneration in glaucoma and other optic neuropathies comprise an unmet clinical need. Histone deacetylases (HDACs) are epigenetic modifiers that repress gene transcription. Here, we identify a role for HDAC4 in RGC neurodegeneration and axon regeneration. Methods: The role of HDAC4 in RGC neuroprotection and axon regeneration was studied in the mouse optic nerve crush (ONC) model for optic neuropathy by RGC transduction in vivo with adeno-associated virus vectors. RGC gene expression in vivo was studied by single cell RNA sequencing (scRNA-seq). Results: A loss-of-function screen identified HDAC4 as essential for RGC survival after ONC injury. Expression of a nuclear-localized HDAC4 missense mutant (HDAC4 3SA) increased RGC survival and axon regeneration after ONC injury. Similar beneficial effects were conferred by an N-terminal fragment of HDAC4 (HDAC4 NT) that can constitutively repress gene expression. The scRNA-seq showed that 1 day after ONC injury, RGC transcriptomic profiles were altered such that HDAC4 NT and to a lesser degree the HDAC4 3SA mutant attenuated the gene expression changes associated with injury. Conclusions: Enhancement of HDAC4 activity promotes RGC survival and axon regeneration in a model of RGC injury, normalizing RGC gene expression toward the uninjured state. HDAC4 is thereby identified as a novel target in the development of therapeutics for RGC protection and restoration of visual function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.